Neratinib
- Generic Name
- Neratinib
- Brand Names
- Nerlynx
- Drug Type
- Small Molecule
- Chemical Formula
- C30H29ClN6O3
- CAS Number
- 698387-09-6
- Unique Ingredient Identifier
- JJH94R3PWB
- Background
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
- Indication
For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
- Associated Conditions
- Breast Cancer
- Associated Therapies
- -
Puma Biotechnology Q3 2024 Earnings: EPS of $0.41 Beats Estimate
Puma Biotechnology reported Q3 2024 revenue of $80.5 million, net income of $20.3 million, and $0.41 per share, exceeding analyst estimates. The company's financial stability is reflected in $97 million in cash, cash equivalents, and marketable securities. Puma continues to focus on NERLYNX commercialization and alisertib development.
Third Quarter 2024 Q3-2024 Commercial Slides
Puma Biotechnology reports $56.1M net NERLYNX revenue in Q3'24, a ~9% increase from Q3'23 and ~26% from Q2'24. 2,723 ex-factory bottles sold, a ~5% decline from Q3'23 but an ~8% increase from Q2'24. ~65% of patients started at a reduced dose. Forward-looking statements involve risks, including COVID-19 impact and regulatory filings.
Puma Biotechnology Reports Third Quarter 2024 Financial Results
Puma Biotechnology reports Q3 2024 net product revenue of $56.1 million, up from $51.6 million in 2023. Total revenue increased to $80.5 million, with net income at $20.3 million. The company focuses on clinical development of alisertib and expects Q4 net product revenue between $46 million and $48 million, revising full-year forecast to $187 million to $190 million.
Puma Biotechnology Reports Inducement Awards
Puma Biotechnology granted a non-executive employee 5,625 restricted stock units, vesting over three years under the 2017 Employment Inducement Incentive Award Plan.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology granted a 5,625-share restricted stock unit award to a new non-executive employee on Nov 4, 2024, under its 2017 Employment Inducement Incentive Award Plan, vesting over three years.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology to host a conference call on November 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST to discuss third quarter financial results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath